Organon & Co. (OGN) Stock Score, Valuation & Financial Research
Organon & Co. is in the Healthcare sector and Drug Manufacturers - General industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 29/100.
Quick answer for OGN
Organon & Co. currently has a Wall Street Score of 29/100. The stored market price is $13.66. Its financial score is 22/100. Its valuation score is 22/100. These figures are a research snapshot, not a buy or sell recommendation.
What Organon & Co. does
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings ext
OGN financial snapshot
- Wall Street Score:
- 29/100
- Current price:
- $13.66
- Market capitalization:
- $3.59B
- Revenue:
- $6.16B
- Net income:
- $246.0M
- Free cash flow:
- $538.0M
- Cash:
- $1.12B
- Total debt:
- $8.57B
- EPS:
- 0.72
- P/E ratio:
- 19.0x
- Financial score:
- 22/100
- Valuation score:
- 22/100
- Revenue score:
- 26/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $538.0M, showing positive cash generation.
- The balance sheet shows $1.12B of cash versus $8.57B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 22/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 22/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research OGN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.